Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citigroup Inc. (C) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Citigroup Inc.Trade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Citigroup Inc. vs Inovio Pharmaceuticals Inc — how do they compare? Citigroup Inc. trades at $135.95 (market cap $226.82B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $76.09M). The key difference: Citigroup Inc. is far larger — about 2980.9× Inovio Pharmaceuticals Inc's market cap, and Citigroup Inc. pays a 1.98% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

CINO
Market Cap
$226.82B$76.09M
Sector
FinancialsHealth
52-Week High
$145.67$2.87
52-Week Low
$92.59$0.66
Dividend Yield
1.98%
Enterprise Value
$47.10M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citigroup Inc.

Citigroup (C) trades at $134.99, up 0.86% with bullish technical momentum near key resistance at $136. The stock shows strong fundamental improvement with Q2 2026 EPS beating estimates at $3.15 versus $2.72 expected, marking the second consecutive quarterly beat. Revenue reached decade highs in Q2 2026 at $91.4B with net income margin improving to 19.52%. Recent strategic hires in investment banking and digital transformation initiatives support growth prospects.

The outlook remains positive with analyst consensus target of $154.38 offering 14% upside potential. Key risks include volatile cash flow patterns with negative operating cash flow in 2025 ($-67.6B) and elevated debt levels at $287.3B long-term debt. The stock's current P/E of 14.55 appears reasonable given improving profitability and strategic repositioning underway.

Inovio Pharmaceuticals Inc

INO trades at $0.668, down 0.86% with bearish technical signals despite recent earnings beats. The company shows minimal revenue of $65,340 against substantial losses, with negative margins and cash flow challenges. Key catalyst is the FDA's October 2026 decision on INO-3107, while recent $20 million offering aims to fund operations.

High-risk biotech play with binary FDA outcome driving valuation. Analyst consensus is bullish (53% buy) with $3.25 price target, but fundamental weaknesses and litigation risks require caution. Success of INO-3107 is critical for turnaround, with current cash funding operations into early 2027.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citigroup Inc.

Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.

Read more on C

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO